You can find our latest news below
February is American Heart Month, emphasizing the importance of heart health, with a focus on women this year due to their unique risk and often underdiagnosed heart conditions. Current AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guidelines for the Evaluation and Diagnosis of Acute Chest Pain highlight the gender-specific nature of heart disease diagnosis, particularly noting that women generally have lower baseline levels of troponin.
At HyTest, we are dedicated to meeting this gender-specific diagnostic need through our innovations in cardiac diagnostics, especially in troponins. Our product range includes approximately 50 antibodies targeting various epitopes of the cardiac troponin I (cTnI) molecule, complemented by our advanced cardiac troponin and troponin complex antigens. For more detailed information, please refer to our Cardiac Markers Brochure.
HyTest antibodies should recognize Pirola and Eris variants.
Procollagen type I N-propetide (PINP) in blood is
recommended as a reference marker for bone formation in osteoporosis by the
International Osteoporosis Foundation (IOF) and the International Federation of
Clinical Chemistry (IFCC) bone marker standards joint working group.
PINP, in particular, has emerged as a recommended reference marker for
bone formation in osteoporosis, aiding in monitoring antiresorptive and
anabolic therapies.
This distinguished award
seeks to recognize and honours outstanding individuals who have made
significant contributions to the field of Cardiovascular Diagnostics.
At HyTest, our specialization in cardiac
troponin (cTn) detection spans nearly three decades.
Over the years, we have generated and analysed
thousands of cTn-specific antibodies.
We're delighted to announce the launch of our latest troponin product: the recombinant chimeric human Cardiac Troponin binary Complex (Cat. # 8IFC20). This unique complex features the most stable part of cTnI (fragment 28-110) linked with TnC by a 20-aar flexible linker of the cTn I – C complex.
We will be attending Medica 2023 in November.
We have been privileged to have Soozy and Linda on our team for about 10 years. Now the story continues with new job descriptions – Soozy Xi will continue as CCO of HyTest and Linda Li will take on the role of General Manager of HyTest China. The whole team warmly congratulates! We also got a few comments from them:
Procalcitonin (PCT) is an established biomarker, which is used to guide antibiotic treatment in septic patient. As an invaluable indicator, it shows high sensitivity and specificity for bacterial infection. Given the utility of PCT in clinical setting, variability in results from different commercial assays have been observed. In this webinar, participants will have the opportunity to review the clinical application of PCT, technology used for PCT measurements and also the challenges in terms of the standardization effort.
#teamhytest is looking forward to meeting our customers at the 2023 AACC Annual Scientific Meeting & Clinical Lab Expo in Anaheim!
We are happy to introduce General Manager of HyTest North America Hut Coats. With Hut in our team, we’re able to be closer to our customers in North America and provide even better service.
The EFLM Award Committee had a difficult task in selecting for the most remarkable scientific work among the submitted papers but in the end Rami Aalto, (University of Turku, Finland) was selected to receive the award.
We are pleased to announce that Netta Keinänen, a valued member of our leadership team, will be stepping into the role of CEO on June 5th, 2023. With her experience, leadership, and strategic vision, we are confident that Netta will continue to lead us to even greater success.
We have launched a new troponin MAb Y302 recombinant monoclonal antibody, which is expressed in a mammalian cell line and contains full-size IgG sequence derived from rabbit B cells and epitope specificity for this MAb is 83 – 100 a.a.r. of human cardiac troponin I.
A new article titled "Fragmentation of human cardiac troponin T after acute myocardial infarction" by our scientists was published in Clinica Chimica Acta journal.
We are launching a new product, recombinant thyroglobulin, Cat # 8RTG4.
Troponin I and T are the main biomarkers and gold standards for diagnostics of acute myocardial infarction (AMI). Recently high- sensitivity cTn (hs-cTn) assays, the detection limit of which is pg/ml (ng/l) rather than ng/ml, have made it possible to identify any myocardial injury, including those AMI patients, within 1 to 3 hours. This represents a potential 3-hour time saving to ensure more rapid patient management.
HF is a severe clinical and public health problem that is characterized by an increasing prevalence and economic cost. NT-proBNP, a derivative of pro-B-type natriuretic peptide (proBNP), is an established biomarker for heart failure (HF) diagnostics.
We will be attending Medlab Middle East 2023 in the beginning of February.
Seasonal flu is an acute respiratory infection caused by influenza viruses, including influenza A and influenza B. The typical symptoms include headaches, running nose, cough and muscle pain. The infection of other respiratory viruses, such as respiratory syncytial virus (RSV), can also present flu-like symptoms.